Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZIIHERA in advanced HER2-positive biliary tract cancer
NCT06282575Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of zanidatamab in biliary tract cancer (BTC), sponsored by Jazz Pharmaceuticals plc. Started Jul 2024; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06282575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282575.